Additionally, the 36-month beta value for CRDL is 1.14. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for CRDL is 65.04M and currently, short sellers hold a 0.42% ratio of that float. The average trading volume of CRDL on May 01, 2024 was 380.78K shares.
CRDL) stock’s latest price update
The stock price of Cardiol Therapeutics Inc (NASDAQ: CRDL) has jumped by 13.56 compared to previous close of 1.77. Despite this, the company has seen a gain of 9.24% in its stock price over the last five trading days. Proactive Investors reported 2024-04-02 that Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) said it had made significant strides in 2023 and early 2024 to advance its offerings of novel therapeutic solutions to patients with underserved heart diseases. In an operational update looking at the 2023 calendar year, CEO David Elsley highlighted some of the main milestones the company achieved.
CRDL’s Market Performance
CRDL’s stock has risen by 9.24% in the past week, with a monthly rise of 4.69% and a quarterly rise of 44.60%. The volatility ratio for the week is 8.99% while the volatility levels for the last 30 days are 8.71% for Cardiol Therapeutics Inc The simple moving average for the past 20 days is 10.02% for CRDL’s stock, with a 76.59% simple moving average for the past 200 days.
Analysts’ Opinion of CRDL
Many brokerage firms have already submitted their reports for CRDL stocks, with H.C. Wainwright repeating the rating for CRDL by listing it as a “Buy.” The predicted price for CRDL in the upcoming period, according to H.C. Wainwright is $9 based on the research report published on April 22, 2024 of the current year 2024.
CRDL Trading at 17.55% from the 50-Day Moving Average
After a stumble in the market that brought CRDL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -7.37% of loss for the given period.
Volatility was left at 8.71%, however, over the last 30 days, the volatility rate increased by 8.99%, as shares surge +11.05% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +40.56% upper at present.
During the last 5 trading sessions, CRDL rose by +9.24%, which changed the moving average for the period of 200-days by +146.96% in comparison to the 20-day moving average, which settled at $1.8400. In addition, Cardiol Therapeutics Inc saw 138.38% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for CRDL
The total capital return value is set at -0.87. Equity return is now at value -69.50, with -56.60 for asset returns.
Based on Cardiol Therapeutics Inc (CRDL), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -152.51.
Currently, EBITDA for the company is -50.12 million with net debt to EBITDA at 1.3. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.36.
Conclusion
In conclusion, Cardiol Therapeutics Inc (CRDL) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
